Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors

NCT00602082 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT00602082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00602082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
December 31, 2009
Enrollment
84 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal carcinoid tumor, islet cell tumor